Safety and efficacy of single agent rovalpituzumab tesirine in small cell lung cancer (SCLC)

Press brief by Charles Rudin, MD, PhD of the Memorial Sloan Kettering Cancer Center, New York, NY, at the 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO), held in Chicago, IL.

Share this video  
Similar topics